Floatz logo

Doxecitine

Mitochondrial Encephalomyopathy

Kenneth Myers, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Mitochondrial Encephalomyopathy cohort.

Asset / SponsorPhaseRating
Sonlicromanol
Khondrion BV
Phase 2B
1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione
Kenneth Myers, MD
Phase 2CCC

Same molecule, other indications

Doxecitine is also rated in:

mitochondrial DNA depletion syndromeDormant
CCC
Indicative ·
53 / 100
View asset →
inborn mitochondrial metabolism disorderDormant
CCC
Indicative ·
53 / 100
View asset →
mitochondrial diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →